Clinical research evaluates new laboratory findings that might advance cancer diagnosis, treatment or prevention in human beings. The OSUCCC – James has hundreds of clinical trials going on at any time. Many are original studies initiated by OSUCCC – James investigators.
OSUCCC – James Clinical Research Strengths
- The OSUCCC – James is one of only a few centers nationally funded by the NCI to conduct both phase I and phase II clinical trials.
- OSUCCC – James investigators have decades of experience designing and conducting phase I and phase II cancer studies.
- The James Cancer Hospital and Solove Research Institute incorporates features designed to facilitate and encourage clinical research.
- Each inpatient floor has translational research labs that bring physicians together with researchers to develop and deliver the most effective targeted therapies for patients
- A dedicated early-phase Clinical Trials Unit offers a comforting patient environment with a staff highly experienced in safely conducting innovative, early-phase trials.
- A state-of-the-art, good manufacturing processes Cellular Processing Laboratory supports the hospital’s 36-bed Blood and Marrow Transplant Unit
- Precision Cancer Medicine at The James uses advanced genomic technologies to identify the molecular changes that cause a patient’s cancer.
- The OSUCCC – James is a comprehensive biomedical research campus with strong collaboration between investigators from the Colleges of Medicine, Pharmacy, Public Health, Nursing, Dentistry and Engineering.
- More than 340 cancer researchers, who collectively represent 11 of the 15 colleges at Ohio State
- Every clinical trial at the OSUCCC – James engages a team of scientists and includes near real-time pharmacokinetics, pharmacodynamics and pharmacogenomics correlative studies.
- OSUCCC – James investigators collaborate extensively with other centers dedicated to experimental therapeutics.
- After defining the safety profile and clinical characteristics of novel agents, OSUCCC – James investigators pursue development of strategic combination regimens.
- OSUCCC – James trials often support new drug approvals by the FDA, while many others are hypothesis-driven therapeutic trials. These include trials for molecular-targeted therapies and genomic profiling of patient tumors, and trials to identify predictive biomarkers.
- Original OSUCCC – James trials include basic scientists who help design the trial and contribute to the discovery of novel therapies.
- Hundreds of their studies published in peer-reviewed medical journals, including more than 100 in journals with impact factors of 10 or above in 2018.
- OSUCCC – James researchers have access to the DDI, a biotech-like institute that employs a combination of targeted investments, strategic management and cutting-edge resources to drive projects from discovery to early-stage development of drugs for cancer therapy.